Nagoya University

Cellmid Limited

Medical Therapies Limited

Takashi Muramatsu

Mitsuru Horiba

Kenji Kadomatsu

Sadatoshi Sakuma

Shinya Ikematsu

Itsuo Kodama

Hisaaki Ishiguro

Hiroharu Takenaka

Arihiro Sumida

A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.

Method to reduce loss of cardiac function following ischemia/reperfusion

The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.

Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation

The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.

Midkine inhibitory compositions for the treatment of angiostenosis

Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA

Growing community of inventors

Aichi, Japan

Mitsuru Horiba